Lenacapavir HIV Prevention: Gilead’s Stra...

By João L. Carapinha

July 10, 2025

Gilead Sciences has finalized a strategic partnership with the Global Fund. The agreement aims to supply lenacapavir HIV prevention, a twice-yearly inject...
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
DALY Modeling Methods for Enhanced Health Economics and Policy Analysis
Pharmaceutical Pricing Issues: Beyond Overpricing and Profit Motives
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...
Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies
RFK Jr.’s ACIP Overhaul: Examining Vaccine Policy Implications
Elsa – FDA AI Tool: Navigating Efficiency and Ethics
Pluvicto Prostate Cancer Trial: Phase III Results
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
Alzheimer’s Blood Test Diagnostics: FDA Clears First Blood Test for Ear...
US Argentina WHO Withdrawal: A Shift in Global Health Governance